chevron_leftBack
As of 13 June 2026, Avalo Therapeutics, Inc. has a market cap of $352.63M USD, ranking #17580 globally and #2936 in the United States.
It ranks #1588 in the Healthcare sector, and #571 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$352.63MUSD
Enterprise Value
$244.57MUSD
Revenue (TTM)
$59.0KUSD
EBITDA (TTM)
-$72.58MUSD
Net Income (TTM)
-$78.26MUSD
PS Ratio
5804.7
PB Ratio
2.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Garry Neil
open_in_new
Employees
33
Founded
2011
IPO
15 Oct 2015
Website
avalotx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.6% | -9% | -5% | -12% | -28% | 179% |
News
Loading...
AVTX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AVTX
Avalo Therapeutics Inc
ISIN: US05338F3064
Shares Out.:
Shares Outstanding:
52.566M1
Shares Float:
47.856M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
13.20 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
216K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
155K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
102K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
78K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
42K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
33K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
91K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
82K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
78K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
51K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
31K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
31K%
80.96B GBP
|
14.6
|
chevron_leftBack